company background image
5410

Bharat Parenterals BSE:541096 Stock Report

Last Price

₹359.15

Market Cap

₹2.1b

7D

15.2%

1Y

-7.2%

Updated

22 May, 2022

Data

Company Financials
541096 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

541096 Stock Overview

Bharat Parenterals Limited researches, develops, manufactures, markets, sources, and distributes pharmaceutical products in India.

Bharat Parenterals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Bharat Parenterals
Historical stock prices
Current Share Price₹359.15
52 Week High₹526.70
52 Week Low₹297.90
Beta1.05
1 Month Change-2.42%
3 Month Change11.85%
1 Year Change-7.17%
3 Year Change77.66%
5 Year Changen/a
Change since IPO125.03%

Recent News & Updates

Shareholder Returns

541096IN PharmaceuticalsIN Market
7D15.2%3.5%3.4%
1Y-7.2%-9.6%9.5%

Return vs Industry: 541096 exceeded the Indian Pharmaceuticals industry which returned -9.6% over the past year.

Return vs Market: 541096 underperformed the Indian Market which returned 9.5% over the past year.

Price Volatility

Is 541096's price volatile compared to industry and market?
541096 volatility
541096 Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.2%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 541096 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 541096's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992286Bharatkumar Desaihttps://bplindia.in

Bharat Parenterals Limited researches, develops, manufactures, markets, sources, and distributes pharmaceutical products in India. The company provides products in the areas of b-lactam antibiotics, anti-retroviral, cephalosporins antibiotics, antiprotozoal/anthelmintic, respiratory, antiallergic/anti-histaminic/anticold, cleansing agents/skin infections, antibiotics, cardiovascular systems, anti-diabetic, anti-tuberculosis, anti-fungal, antimalarial, gastrointestinal tract/alimentary systems, anti-inflammatory/anti-pyretic/analgesics, supplements, central nervous system, anaesthetics, anti-viral, steroids and hormones, uterine stimulant, anticancer, and others. It also provides general products, ß-lactum/cephalosporin products, and formulations in the form of tablets, capsules, liquid-orals, ointments, creams, lotions, suspensions, nebulizers, elixiers, eye drops, infusions, nasal drops, and powdered injections, as well as in ampoules and vials.

Bharat Parenterals Fundamentals Summary

How do Bharat Parenterals's earnings and revenue compare to its market cap?
541096 fundamental statistics
Market Cap₹2.07b
Earnings (TTM)₹188.99m
Revenue (TTM)₹2.03b

11.0x

P/E Ratio

1.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
541096 income statement (TTM)
Revenue₹2.03b
Cost of Revenue₹1.30b
Gross Profit₹732.26m
Other Expenses₹543.27m
Earnings₹188.99m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 28, 2022

Earnings per share (EPS)32.73
Gross Margin36.09%
Net Profit Margin9.31%
Debt/Equity Ratio7.0%

How did 541096 perform over the long term?

See historical performance and comparison

Valuation

Is Bharat Parenterals undervalued compared to its fair value and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


7.3%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 541096 (₹359.15) is trading below our estimate of fair value (₹387.28)

Significantly Below Fair Value: 541096 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 541096 is good value based on its PE Ratio (11x) compared to the Indian Pharmaceuticals industry average (21.5x).

PE vs Market: 541096 is good value based on its PE Ratio (11x) compared to the Indian market (20.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 541096's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 541096 is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.6x).


Future Growth

How is Bharat Parenterals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bharat Parenterals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Bharat Parenterals performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 541096 has high quality earnings.

Growing Profit Margin: 541096's current net profit margins (9.3%) are lower than last year (11.5%).


Past Earnings Growth Analysis

Earnings Trend: 541096's earnings have grown significantly by 22.2% per year over the past 5 years.

Accelerating Growth: 541096's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 541096 had negative earnings growth (-26.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).


Return on Equity

High ROE: 541096's Return on Equity (11.3%) is considered low.


Financial Health

How is Bharat Parenterals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 541096's short term assets (₹1.7B) exceed its short term liabilities (₹523.3M).

Long Term Liabilities: 541096's short term assets (₹1.7B) exceed its long term liabilities (₹98.5M).


Debt to Equity History and Analysis

Debt Level: 541096 has more cash than its total debt.

Reducing Debt: 541096's debt to equity ratio has reduced from 15.5% to 7% over the past 5 years.

Debt Coverage: 541096's debt is well covered by operating cash flow (199.8%).

Interest Coverage: 541096's interest payments on its debt are well covered by EBIT (71.6x coverage).


Balance Sheet


Dividend

What is Bharat Parenterals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 541096's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 541096's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 541096's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 541096's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 541096 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average board tenure


CEO

Bharatkumar Desai (58 yo)

no data

Tenure

₹13,026,250

Compensation

Mr. Bharatkumar Rameshchandra Desai serves as Chairman and Managing Director of Bharat Parenterals Limited.


CEO Compensation Analysis

Compensation vs Market: Bharatkumar's total compensation ($USD167.41K) is above average for companies of similar size in the Indian market ($USD38.56K).

Compensation vs Earnings: Bharatkumar's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 541096's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bharat Parenterals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Bharat Parenterals Limited
  • Ticker: 541096
  • Exchange: BSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹2.074b
  • Shares outstanding: 5.77m
  • Website: https://bplindia.in

Number of Employees


Location

  • Bharat Parenterals Limited
  • Shree Avenue
  • 1st Floor,Above Bank of Baroda
  • Vadodara
  • Gujarat
  • 390022
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.